Interleukin 4, Interleukin 13, and Interleukin 9

Inflammation and Allergy Drug Design

Volumn , Issue , 2011, Pages 173-185

  Izuhara, Kenji ^a   Ohta, Shoichiro ^a   Shiraishi, Hiroshi ^a   Suzuki, Shoichi ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Chitinase chitinase like protein including acidic mammalian chitinase (AMCase); Cytokines, contributing to pathogenesis of allergic diseases, in respiratory tract; IL 13, acting as central mediator in asthma pathogenesis, in mice; IL 13, dominant in pathogenesis of bronchial asthma, compared with IL 4; IL 4, factor for Th2 type inflammation inducing Th2 differentiation, class switching into IgE in B cells; IL 9 application, in development as therapeutic agent for bronchial asthma; Interleukin 4, interleukin 13 and interleukin; Jak STAT pathways, main signal pathways for IL 4 IL 13, and other cytokines; Signal transduction of IL 4 IL 13 IL 4 and IL 13, binding to their specific receptors; Therapeutic reagents, against bronchial asthma targeting interleukin 4 (IL 4) and IL 13

Indexed keywords

EID: 84861504129     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444346688.ch13     Document Type: Chapter

References (99)

1. Izuhara K, Arima K, Yasunaga S. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Curr Drug Targets Inflamm Allergy 2002; 1: 263-9.
2. Izuhara K, Arima K, Kanaji S, et al. IL-13: a promising therapeutic target for bronchial asthma. Curr Med Chem 2006; 13: 2291-8.
3. Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13 a2 receptor is involved in induction of TGF -ß1 production and fibrosis. Nat Med. 2006; 12: 99-106.
4. Junttila IS, Mizukami K, Dickensheets H, et al. Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4R a, IL-13R a1: and yc regulates relative cytokine sensitivity. J Exp Med 2008; 205: 2595-608.
5. Arima K, Sato K, Tanaka G, et al. Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem 2005; 280: 24915-22.
6. LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008; 132: 259-72.
7. Ito T, Suzuki S, Kanaji S, et al. Distinct structural requirements for interleukin-4 (IL-4) and IL-13 binding to the shared IL-13 receptor facilitate cellular tuning of cytokine responsiveness. J Biol Chem 2009; 284: 24289-96.
8. Kotsimbos TC, Ernst P, Hamid QA. Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc Assoc Am Phys 1996; 108: 368-73.
9. Bodey KJ, Semper AE, Redington AE, et al. Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. Allergy 1999; 54: 1083-93.
10. Truyen E, Coteur L, Dilissen E, et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax 2006; 61: 202-8.
11. Brusselle G, Kips J, Joos G, et al. Allergen-induced airway inflammation and bronchial responsiveness in wild type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol 1995; 12: 254-9.
12. Hogan SP, Mould A, Kikutani H, et al. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest 1997; 99: 1329-39.
13. Hogan SP, Matthaei KI, Young JM, et al. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol 1998; 161: 1501-9.
14. Corry DB, Folkesson HG, Warnock ML, et al. Interleukin 4: but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183: 109-17.
15. Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13: IL-4: and IL-5 regulate airways hyperreactivity. J Immunol 2000; 165: 108-13.
16. Grünig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261-3.
17. Akimoto T, Numata F, Tamura M, et al. Abrogation of bronchial eosinophilic inflammation and airway hyper-reactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med 1998; 187: 1537-42.
18. Tomkinson A, Kanehiro A, Rabinovitch N, et al. The failure of STAT6-deficient mice to develop airway eosi-nophilia and airway hyperresponsiveness is overcome by interleukin-5. Am J Respir Crit Care Med 1999; 160: 1283-91.
19. Blease K, Schuh JM, Jakubzick C, et al. Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am J Pathol 2002; 160: 481-90.
20. Venkayya R, Lam M, Willkom M, et al. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol 2002; 26: 202-8.
21. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-61.
22. Blease K, Jakubzick C, Westwick J, et al. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol 2001; 166: 5219-24.
23. Walter DM, McIntire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 2001; 167: 4668-75.
24. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hyperse-cretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103: 779-88.
25. Kuperman DA, Huang X, Koth LL, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyper-reactivity and mucus overproduction in asthma. Nat Med 2002; 8: 885-9.
26. Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir Res 2003; 4: 14.
27. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 2008; 8: 169-82.
28. Rosenwasser LJ, Borish L. Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am J Respir Crit Care Med 1997; 156: S152-5.
29. Arima K, Umeshita-Suyama R, Sakata Y, et al. Upregulation of IL-13 concentration in vivo by the IL-13 variant associated with bronchial asthma. J Allergy Clin Immunol 2002; 109: 980-7.
30. Chen W, Ericksen MB, Levin LS, et al. Functional effect of the R110Q IL-13 genetic variant alone and in combination with IL-4RA genetic variants. J Allergy Clin Immunol 2004; 114: 553-60.
31. Vladich FD, Brazille SM, Stern D, et al. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J Clin Invest 2005; 115: 747-54.
32. Yoshida Y, Ohkuri T, Takeda C, et al. Analysis of internal motions of interleukin-13 variant associated with severe bronchial asthma using (15)N NMR relaxation measurements. Biochem Biophys Res Commun 2007; 358: 292-7.
33. Mitsuyasu H, Izuhara K, Mao XQ, et al. Ile50Val variant of IL-4R a upregulates IgE synthesis and associates with atopic asthma. Nat Genet 1998; 19: 119-20.
34. Hershey GK, Friedrich MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the a subunit of the interleukin-4 receptor. N Engl J Med 1997; 337: 1720-5.
35. Tachdjian R, Mathias C, Al Khatib S, et al. Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma. J Exp Med 2009; 206: 2191-204.
36. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202: 175-90.
37. Lee JH, Kaminski N, Dolganov G, et al. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol 2001; 25: 474-85.
38. Yuyama N, Davies DE, Akaiwa M, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine 2002; 19: 287-96.
39. Zou J, Young S, Zhu F, et al. Microarray profile of differentially expressed genes in a monkey model of allergic asthma. Genome Biol 2002; 3: research0020.
40. Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003; 111: 1863-74.
41. Nakanishi A, Morita S, Iwashita H, et al. Role of gob-5 in mucus overproduction and airway hyperresponsive-ness in asthma. Proc Natl Acad Sci USA 2001; 98: 5175-80.
42. Toda M, Tulic MK, Levitt RC, et al. A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol 2002; 109: 246-50.
43. Kuperman DA, Lewis CC, Woodruff PG, et al. Dissecting asthma using focused transgenic modeling and functional genomics. J Allergy Clin Immunol 2005; 116: 305-11.
44. Robichaud A, Tuck SA, Kargman S, et al. Gob-5 is not essential for mucus overproduction in preclinical murine models of allergic asthma. Am J Respir Cell Mol Biol 2005; 33: 303-14.
45. Long AJ, Sypek JP, Askew R, et al. Gob-5 contributes to goblet cell hyperplasia and modulates pulmonary tissue inflammation. Am J Respir Cell Mol Biol 2006; 35: 357-65.
46. Gibson A, Lewis AP, Affleck K, et al. hCLCA1 and mCLCA3 are secreted nonintegral membrane proteins and therefore are not ion channels. J Biol Chem 2005; 280: 27205-12.
47. Zhu Z, Zheng T, Homer RJ, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004; 304: 1678-82.
48. Cai Y, Kumar RK, Zhou J, et al. Ym1/2 promotes Th2 cytokine expression by inhibiting 12/15(S)-lipoxygenase: identification of a novel pathway for regulating allergic inflammation. J Immunol 2009; 182: 5393-9.
49. Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009; 206: 1149-66.
50. Bierbaum S, Nickel R, Koch A, et al. Polymorphisms and haplotypes of acid mammalian chitinase are associated with bronchial asthma. Am J Respir Crit Care Med 2005; 172: 1505-9.
51. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008; 358: 1682-91.
52. Chupp GL, Lee CG, Jarjour N, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007; 357: 2016-27.
53. Nakao I, Kanaji S, Ohta S, et al. Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease. J Immunol 2008; 180: 6262-9.
54. Nakagami Y, Favoreto S, Jr., Zhen G, et al. The epithelial anion transporter pendrin is induced by allergy and rhinovirus infection, regulates airway surface liquid, and increases airway reactivity and inflammation in an asthma model. J Immunol 2008; 181: 2203-10.
55. Salam MT, Islam T, Gauderman WJ, et al. Roles of arginase variants, atopy, and ozone in childhood asthma. J Allergy Clin Immunol 2009; 123: 596-602: e591-8.
56. Morris CR, Poljakovic M, Lavrisha L, et al. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 2004; 170: 148-53.
57. Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118: 98-104.
58. Hayashi N, Yoshimoto T, Izuhara K, et al. T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN -? and IL-13 production. Proc Natl Acad Sci USA 2007; 104: 14765-70.
59. Blanchard C, Mingler MK, McBride M, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 2008; 1: 289-96.
60. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104: 15858-63.
61. Tony HP, Shen BJ, Reusch P, et al. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur J Biochem 1994; 225: 659-65.
62. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-31.
63. Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40: a mouse glycoprotein with T-cell growth factor activity.Proc Natl Acad Sci USA 1988; 85: 6934-8.
64. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442: 997-1002.
65. Elyaman W, Bradshaw EM, Uyttenhove C, et al. -L-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA 2009; 106: 12885-90.
66. Nowak EC, Weaver CT, Turner H, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009; 206: 1653-60.
67. Asao H, Okuyama C, Kumaki S, et al. The common ?-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001; 167: 1-5.
68. Demoulin JB, Uyttenhove C, Van Roost E, et al. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT, activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol 1996; 16: 4710-16.
69. Demoulin JB, Uyttenhove C, Lejeune D, et al. STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells. Cancer Res 2000; 60: 3971-7.
70. Levitt RC, McLane MP, MacDonald D, et al. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol 1999; 103: S485-91.
71. Reader JR, Hyde DM, Schelegle ES, et al. Interleukin-9 induces mucous cell metaplasia independent of inflammation. Am J Respir Cell Mol Biol 2003; 28: 664-72.
72. Godfraind C, Louahed J, Faulkner H, et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol 1998; 160: 3989-96.
73. McLane MP, Haczku A, van de Rijn M, et al. Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Am J Respir Cell Mol Biol 1998; 19: 713-20.
74. Dong Q, Louahed J, Vink A, et al. IL-9 induces chem-okine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Eur J Immunol 1999; 29: 2130-9.
75. Louahed J, Toda M, Jen J, et al. Interleukin-9 upregu-lates mucus expression in the airways. Am J Respir Cell Mol Biol 2000; 22: 649-56.
76. van den Brule S, Heymans J, Havaux X, et al. Profibrotic effect of IL-9 overexpression in a model of airway remodeling. Am J Respir Cell Mol Biol 2007; 37: 202-9.
77. Temann UA, Geba GP, Rankin JA, et al. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998; 188: 1307-120.
78. Temann UA, Ray P, Flavell RA. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology.J Clin Invest 2002; 109: 29-39.
79. Steenwinckel V, Louahed J, Orabona C, et al. IL-13 mediates-n vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol 2007; 178: 3244-51.
80. Whittaker L, Niu N, Temann UA, et al. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol 2002; 27: 593-602.
81. McMillan SJ, Bishop B, Townsend MJ, et al. The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med 2002; 195: 51-7.
82. Kung TT, Luo B, Crawley Y, et al. Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. Am J Respir Cell Mol Biol 2001; 25: 600-5.
83. Cheng G, Arima M, Honda K, et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 2002; 166: 409-16.
84. Longphre M, Li D, Gallup M, et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest 1999; 104: 1375-82.
85. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma.J Allergy Clin Immunol 2000; 105: 108-15.
86. Erpenbeck VJ, Hohlfeld JM, Volkmann B, et al. Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoal-veolar lavage fluid lymphocytes. J Allergy Clin Immunol 2003; 111: 1319-27.
87. Bhathena PR, Comhair SA, Holroyd KJ, et al. Interleukin-9 receptor expression in asthmatic airways in vivo. Lung 2000; 178: 149-60.
88. Doull IJ, Lawrence S, Watson M, et al. Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness. Am J Respir Crit Care Med 1996; 153: 1280-4.
89. Melen E, Umerkajeff S, Nyberg F, et al. Interaction between variants in the interleukin-4 receptor a and interleukin-9 receptor genes in childhood wheezing: evidence from a birth cohort study. Clin Exp Allergy 2006; 36: 1391-8.
90. Nicolaides NC, Holroyd KJ, Ewart SL, et al. Interleukin 9: a candidate gene for asthma. Proc Natl Acad Sci USA 1997; 94: 13175-80.
91. Renauld JC, Goethals A, Houssiau F, et al. Cloning and expression of a cDNA for the human homolog of mouse T cell and mast cell growth factor P40. Cytokine 1990; 2: 9-12.
92. Bourette RP, Royet J, Mouchiroud G, et al. Murine inter-leukin 9 stimulates the proliferation of mouse erythroid progenitor cells and favors the erythroid differentiation of multipotent FDCP-mix cells. Exp Hematol 1992; 20: 868-73.
93. Louahed J, Zhou Y, Maloy WL, et al. Interleukin 9 promotes influx and local maturation of eosinophils. Blood 2001; 97: 1035-42.
94. Abdelilah S, Latifa K, Esra N, et al. Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release. J Immunol 2001; 166: 2768-74.
95. Little FF, Cruikshank WW, Center DM. IL-9 stimulates release of chemotactic factors from human bronchial epithelial cellsAm J Respir Cell Mol Biol 2001; 25: 347-52.
96. Baraldo S, Faffe DS, Moore PE, et al. Interleukin-9 influences chemokine release in airway smooth muscle: role of ERK. Am J Physiol Lung Cell Mol Physiol 2003; 284: L1093-102.
97. Gounni AS, Hamid Q, Rahman SM, et al. IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J Immunol 2004; 173: 2771-9.
98. Chen Y, Thai P, Zhao YH, et al. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 2003; 278: 17036-43.
99. White B, Leon F, White W, et al. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528: a monoclonal antibody against interleukin-9: in healthy adult volunteers. Clin Ther 2009; 31: 728-40.